Janux Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $24M+126.7% YoYTTM through 30 Jun 2026
Net Income -$102.6MTTM through 30 Jun 2026
Free Cash Flow -$41.9MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | -589.7% |
| Operating Margin | -915.3% |
| Net Margin | -427.5% |
Returns
-2.6%ROE
-2.4%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio39.04x
Net Debt-$956.4Mnet cash position
Cash & Equivalents$27.8M
Quality Metrics
Altman Z-Score8.14
Piotroski F-Score2 / 9
FCF Margin-174.7%
Rule of 40-151.9
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $10M
Diluted EPS-$1.64TTMFY2025: $-1.83
Dividend
No dividend
Capital Allocation
Capex Intensity2.8%
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.